LMR Partners’s AstraZeneca AZN Stock Holding History

LMR Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,950	Closed	-$6.79M	–	1462
2025 Q4	$6.79M	Hold	36,950	–	–	0.01%	499
2025 Q3	$5.67M	Hold	36,950	–	–	0.03%	476
2025 Q2	$5.16M	Sell	36,950 -57,150	-61%	-$8.01M	0.04%	431
2025 Q1	$13.8M	Sell	94,100 -10,850	-10%	-$1.57M	0.13%	185
2024 Q4	$13.8M	Buy	+104,950	New	+$14.7M	0.12%	176
2023 Q4	–	Sell	-89,350	Closed	-$12.1M	–	996
2023 Q3	$12.1M	Buy	89,350 +11,700	+15%	+$1.6M	0.14%	165
2023 Q2	$11.1M	Buy	+77,650	New	+$11.4M	0.12%	178

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LMR Partners's AZN Position: Q2 2026 in Review

LMR Partners reduced its AstraZeneca (AZN) stake by 24% in Q2 2026, selling an estimated $940K and leaving 15,425 shares worth $2.92M. The position accounts for 0.01% of the portfolio, ranked #797.

LMR Partners first reported a position in AZN in Q2 2020 and has held it in 18 quarters since. The position peaked at $130M in Q4 2025. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

LMR Partners held 15,425 shares of AstraZeneca worth $2.92M as of Q2 2026.
LMR Partners sold 5,000 AstraZeneca shares in Q2 2026, an estimated $940K.
AstraZeneca made up 0.01% of LMR Partners's portfolio in Q2 2026, its #797 holding.
LMR Partners first reported a position in AstraZeneca in Q2 2020 and has held it in 18 quarters since.
LMR Partners's AstraZeneca position peaked at $130M in Q4 2025.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.